Arcus ends Phase 3 STAR-221 domvanalimab study on futility; no OS benefit

Arcus Biosciences, Inc.

Phase 3 STAR-221 of domvanalimab + zimberelimab + chemo vs nivolumab + chemo stopped for futility after IDMC review.
Domvanalimab combo did not improve overall survival vs nivolumab + chemo; safety profile similar.
Phase 2 EDGE-Gastric also discontinued; company and Gilead communicating with investigators.
R&D focus shifts to HIF-2a inhibitor casdatifan and small molecule inflammation programs; MRGPRX2 inhibitor clinical entry expected 2026.
Cash runway expected to fund operations until at least second half 2028.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.